First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Abstract Background A cytotoxic chemotherapeutic regimen is not routinely recommended for frail elderly patients with unresectable colorectal cancer (CRC) because of susceptibility to treatment. Panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Use of panitu...

Full description

Bibliographic Details
Main Authors: Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Yoshihiro Matsubara, Taroh Satoh
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Frail patient
Panitumumab
Clinical trial-trial design
Online Access:http://link.springer.com/article/10.1186/s12885-019-5821-z

Internet

http://link.springer.com/article/10.1186/s12885-019-5821-z

Similar Items